Stifel Nicolaus Upgrades Idenix Pharmaceuticals Inc. (IDIX) to Hold
Tweet
Share
E-mailGet Alerts IDIX Hot Sheet
Price: $24.50 --0%
Rating Summary:
1 Buy, 14 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
1 Buy, 14 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Stifel Nicolaus upgraded Idenix Pharmaceuticals Inc. (NASDAQ: IDIX) from Sell to Hold, with shares under heavy pressure after the company announced that hepatitis C drug IDX184 has been placed on partial clinical hold by the FDA due to a serious cardiac-related adverse event.
For an analyst ratings summary and ratings history on Idenix Pharmaceuticals Inc. click here. For more ratings news on Idenix Pharmaceuticals Inc. click here.
Shares of Idenix Pharmaceuticals are down 30 percent, but off the day's lows.
For an analyst ratings summary and ratings history on Idenix Pharmaceuticals Inc. click here. For more ratings news on Idenix Pharmaceuticals Inc. click here.
Shares of Idenix Pharmaceuticals are down 30 percent, but off the day's lows.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stifel Upgrades Intuitive Machines Inc. (LUNR) to Buy
- Freedom Broker Upgrades Serve Robotics (SERV) to Buy
- CIBC Upgrades PRO REIT (PRV-U:CN) to Outperformer
Create E-mail Alert Related Categories
UpgradesRelated Entities
StifelSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
